10.01.26 -- What Makes ADC Tech Transfers So Difficult?

See how higher API activity is changing expectations around containment, scalability, and cross‑functional alignment — and why early decisions now have a greater impact on long‑term success.

Explore how to select the right CDMO partner for your pharmaceutical project to navigate the evolving drug development landscape and ensure successful outcomes.

Learn how continuity planning, technology transfer capabilities, global network flexibility, and digital visibility contribute to resilient supply chains and help protect programs from disruption.

Outlined here are the benefits of PFS and how they relate to the delivery of drugs, how SARS-CoV-2 could be fueling an explosive increase in PFS demand, and how a partnership is the key to success.

Embedding manufacturing and regulatory readiness early streamlines development, reduces delays, and supports successful scale-up.

Biologic lot testing spans bulk harvest to final stability. Core panels check purity, safety, identity, and potency to ensure compliance, low risk, and high product quality across production.

Legacy facilities weren't built for today's cold chain complexity. How are CDMOs squeezing more capacity from fixed footprints without breaking what already works?

Middlesex County, NJ, is a premier life sciences hub, attracting major biopharma leaders, entrepreneurs, and investors to accelerate global medical innovation.